Cambridge Investment Research Advisors
BDSI

Cambridge Investment Research Advisors’s BioDelivery Sciences International, Inc. BDSI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BDSI Stock Details BDSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-71,009
Closed -$220K – 3378
2021
Q4 		$220K Buy
+71,009
New +$239K ﹤0.01% 2800
2021
Q2 		– Sell
-10,141
Closed -$40K – 3210
2021
Q1 		$40K Buy
+10,141
New +$41.9K ﹤0.01% 2819
2020
Q1 		– Sell
-11,530
Closed -$73K – 2560
2019
Q4 		$73K Buy
11,530
+150
+1% +$882 ﹤0.01% 2338
2019
Q3 		$48K Buy
+11,380
New +$48.6K ﹤0.01% 2285

Other funds holding BDSI

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $231M AUM 61.68% 1-Year Est. Return

Cambridge Investment Research Advisors's BDSI Position: Q1 2022 in Review

Cambridge Investment Research Advisors sold out of BioDelivery Sciences International, Inc. (BDSI) in Q1 2022, closing a stake of 71,009 shares — an estimated $220K sold.

Cambridge Investment Research Advisors first reported a position in BDSI in Q3 2019 and held it in 4 quarters. The position peaked at $220K in Q4 2021. 2 funds tracked by Wall St. Rank hold BDSI as of Q1 2022.

  • Cambridge Investment Research Advisors reported no remaining BioDelivery Sciences International, Inc. position as of Q1 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 71,009 BioDelivery Sciences International, Inc. shares in Q1 2022, an estimated $220K.
  • Cambridge Investment Research Advisors first reported a position in BioDelivery Sciences International, Inc. in Q3 2019 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's BioDelivery Sciences International, Inc. position peaked at $220K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held BioDelivery Sciences International, Inc. as of Q1 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2022, filed 12 May 2022.